Recombinant T-cell Receptor Ligand RTL1000 Limits inflammation and Decreases Infarct Size after Experimental Ischemic Stroke in Middle-Aged Mice

We have previously demonstrated that recombinant T-cell receptor ligand 1000 (RTL1000) reduces infarct size and improves long-term functional recovery after experimental stroke in young transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). In this study, we determined the effect of RTL100...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuroscience
Egile Nagusiak: Zhu, W., Dotson, A. L., Libal, N. L., Lapato, A. S., Bodhankar, S., Offner, H., Alkayed, N. J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323943/
https://ncbi.nlm.nih.gov/pubmed/25556831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuroscience.2014.12.037
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak